Recent studies of the molecular basis of myeloid transformation have led to the identification of novel intracellular targets for leukemia therapy. The first group of agents developed to target a specific enzymatic pathway in acute myeloid leukemia (AML) was the ribonucleotide reductase inhibitors, including fludarabine, cladrabine, clofarabin, and, most recently, gemcitabine. Other intracellular targets for which small molecule inhibitors or biomodulators have been identified include histone deacetylase, protein kinase C, farnesyl transferase, and cyclin-D. Antibodies targeting cell surface receptors on myeloid cells, such as CD33, have been engineered and have demonstrated efficacy alone and, more recently, in immunoconjugates. In addition to the identification of novel agents, rational strategies to combine targeted therapies with conventional cytotoxic agents are being explored.
Anthracyclines have traditionally been a mainstay of AML therapy. Idarubicin is the most recent anthracycline to be developed. The availability of oral idarubicin has led to the development of outpatient anthracycline-based therapies for elderly or refractory patients. A study of weekly oral idarubicin at a dose of 20 mg/m 2 administered weekly for 4 weeks with a second induction at 40 mg/m 2 × 4 weeks in a group of elderly AML patients demonstrated a complete response rate of 25% with 4% partial responses. 1 The disease-free survival was 9.6 months. One-third of the patients did not require hospitalization, and the median number of hospital days for those requiring hospitalization was 14.5. Oral idarubicin was both safe and effective in this group of elderly AML patients.
Another anthracycline, daunorubicin, has been encapsulated into liposomes (DaunoXome, NeXstar Pharmaceuticals, Boulder, CO, USA) with the hope of decreasing toxicity and perhaps increasing efficacy. In phase I studies at the MD Anderson, 2 24 patients were treated at doses of 75-200 mg/m 2 for 3 consecutive days. The dose-limiting toxicity was mucositis. Of significance, there was no change in left ventricular ejection fraction and no apparent clinical cardiac toxicity. The maximum tolerated dose (MTD) for phase II trials was determined to be 150 mg/m 2 /day × 3 days. Another novel drug, troxacitabine, is a nucleoside that is in the L isomer configuration, unlike naturally occurring nucleosides and all other nucleoside analogue drugs, which are in the D configuration. This is important because the activating enzymes for drugs like cytarabine and gemcitabine are not stereospecific, but the deactivating enzymes are. Troxacitabine is triphosphorylated within cells, but is then resistant to cytidine deaminase and thus has a very long half-life in the cell. It inhibits DNA polymerase, but perhaps more importantly, it is a DNA chain terminator. In a phase I trial of Interestingly, the dose-limiting toxicity was hand-foot syndrome, although myelosuppression, skin rash, and stomatitis were also seen. The drug was primarily excreted through the kidney, with a mean half-life of 100 h. Thirty-six percent of patients with advanced refractory leukemia achieved marrow hypocellularity, and three had a complete remission. Phase II trials are currently underway with this promising agent.
Topotecan is a topoisomerase-1 inhibitor that has demonstrated activity in myelodysplastic syndromes and AML. 4 At a dose of 2 mg/m 2 continuous i.v. infusion (CIV) daily × 5, the response rate was 31%. 5 The combination of topotecan (1.25 mg/m 2 /day × 5) with cytarabine (1 g/m 2 over 2 h) had a higher response rate of 56%. 6 Importantly, the response rate in patients with complex cytogenetic abnormalities, including abnormalities of chromosomes 5 and 7, appeared to be higher with these combinations than with conventional combinations of cytarabine and daunorubicin.
Since it has been shown that expression of topoisomerase-2 increases after topoisomerase-1 therapy, phase I studies have been undertaken with this combination. In one study, topotecan was administered at a dose of 1.5 mg/m 2 CIV × 5 days, with etoposide 100 mg/m 2 on days 6, 7 and 8. In another study, the topoisomerase-2 inhibitor, daunorubicin, was administered with topotecan, either sequentially or on a concurrent schedule. In this study, topotecan was administered CIV at a dose of 1.25 mg/m 2 /day × 3 followed by DaunoXome administered at a dose of 100 mg/m 2 daily × 3. The dose-limiting toxicities were mucositis and diarrhea. The concurrent schedule used the same dose of topotecan with DaunoXome 75 mg/m 2 daily; this was felt to be superior and is being further explored. Another DNA-damaging agent, cyclophosphamide, has been combined with ara-C and topotecan for AML, again concentrating on patients with adverse cytogenetic findings. In one study of 83 patients, the complete response rate was 36%. 7 However, the three-drug combination was somewhat more toxic, with a 13% mortality rate.
The CD33 antigen is expressed on myeloblasts in about 80% of AML patients and on all cases of acute promyelocytic leukemia (APL). It may be present on the leukemia progenitor cell, but appears to be absent from the surface of the pluripotent normal hematopoietic stem cell. Since this antigen receptor complex internalizes ligand, it can serve as a vehicle for targeted therapy.
The M195 antibody is a humanized anti-CD33 monoclonal. In a study at Memorial Sloan-Kettering Cancer Center, 22 patients with APL who were still RT-PCR positive after induction therapy with all-trans retinoic acid (ATRA) received humanized M195 as a naked antibody twice weekly for 3 weeks. 8 Half of the patients became RT-PCR negative. They continued to receive monthly maintenance courses of the antibody together with three consolidation courses with idarubicin and cytarabine. About 93% of these patients remain in complete remission with a median follow-up of 29 months (range, 7-58 months). In patients with more advanced APL in the second or third complete response, only one became RT-PCR negative after treatment. This antibody has been subsequently conjugated to I 131 and to bismuth-213; these radionuclide conjugates have been used in preparation for bone marrow transplantation. Antibody-dependent cellular cytotoxicity appears to be the mechanism by which leukemic cells are destroyed after M195 binds to their surface and at least one group has now begun studying the combination of interleukin-2 with M195 in patients with leukemia.
CMA-676 is a conjugation of an anti-CD33 antibody with calicheamicin, a potent antitumor antibiotic that has intracellular activity similar to the anthracyclines in that it binds DNA in the minor groove and produces double-strand breaks. The antibody binds to the surface of the cell and is internalized. The linker is hydrolyzed, releasing free calicheamycin into the cytoplasm of the cell where it then translocates to the nucleus and binds DNA. Importantly, this drug seems to be effluxed from the cell by P-glycoprotein. 9 At doses of 6-9 mg/m 2 , there is rapid saturation of CD33 binding sites within 30 min. The half-life of the antibody in plasma is about 2.5 days. 10 In phase II trials, CMA-676 was given at a dose of 9 mg/m 2 intravenously as a 2-h infusion for two doses 14 days apart, and patients were evaluated at day 28. 11 Of 142 patients treated on study, the overall remission rate was 30%. Half of the responders achieved complete remissions with fewer than 5% blasts in the bone marrow, greater than 1500 neutrophils per l, and greater than 100 000 platelets. The other half achieved the response criteria for a complete remission with the exception that their platelet count never recovered fully to 100 000. These patients were enrolled on three separate trials. The 201 trial was conducted in the US and enrolled 65 patients over the age of 18 years who had been in remission for longer than 6 months. The 202 trial enrolled 40 patients in Europe and the 203 trial enrolled 37 in the US and Canada. The 203 trial enrolled patients over the age of 60 and patients whose first remission had lasted only 3 months. The response rates for the 202 and 203 studies were 33% and 22%, respectively.
Since age and duration of first remission have been predictors of outcome for treatment of first relapse, these prognostic factors were examined in the treated patients. In patients under 60 years old with duration of first remission less than 12 months, the response rate was 36% (12/33 patients), while in those over 60 it was 21% (10/47 patients). In patients whose remission was longer than 12 months, there was no difference in response rates for the two age groups (31% vs 33%). Interestingly, this drug was approved for the treatment of first relapse for patients over the age of 60 based in part on its more favorable toxicity spectrum. The median survival for the 142 patients was 5.9 months and the survival at 12 months was 31%. Most, but not all, of the long-term survivors have undergone bone marrow transplantation.
Future studies with CMA-676 could include up-front administration on day 1 followed by standard cytarabine/ daunorubicin induction on day 8 for those patients who were not already hypoplastic. It has been our experience that the patients who have responded best to CMA-676 have already had marked marrow hyperplasia by day 8 and it may be possible to induce some patients into remission with the immunoconjugate alone, sparing the toxicity associated with standard induction regimens. It could also be administered together with a 7-day infusion of cytarabine in place of the daunorubicin or, alternatively, added to a standard cytarabine/ daunorubicin regimen as a way of boosting the anthracycline effect within the targeted cells and minimizing the toxic effects of higher doses of anthracycline in non-CD33 expressing normal cells. This drug may also be of some use in postremission therapy (schedules of administration once every 6 to 8 weeks have been proposed at the completion of cytotoxic therapy) and in preparative regimens prior to bone marrow transplantation or after recovery from autologous transplantation to try to reduce the relapse rate. Given its more favorable toxicity spectrum, it might potentially be used in older patients with myelodysplastic syndrome. All of these strategies are now being explored in clinical trials.
Over the past several years, treatment outcomes for AML appear to have plateaued. Although the majority of patients achieve an initial remission, most will eventually suffer a relapse and die from complications due to progressive leukemia. At the same time, basic research has identified various mechanisms of drug resistance as well as a number of signaling pathways that are involved in cell proliferation and apoptosis. Our present and future challenge is to develop new therapeutics for these molecular targets and then to individualize therapy according to the biological determinants of each patient's leukemia. In this way, we hope to provide the greatest likelihood of disease-free survival with the least toxicity.
